CDA | Evidence Driven
CDA | Evidence Driven

Dabrafenib trametinib

Details

Files
Generic Name:
Dabrafenib trametinib
Project Status:
Active
Therapeutic Area:
Head and neck cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0373-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Indicated for BRAF V600E mutant anaplastic thyroid cancer.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission received17-Oct-24
Review initiated17-Oct-24
Expert committee meeting (initial)20-Mar-25

Files

Proposed Scope View PDF

Related Content

Last Updated : October 22, 2024